GSK3B and lung carcinoma: To evaluate the in vivo therapeutic effect of the GSK3β inhibitor on lung cancer with FHIT loss, we performed tumor xenograft experiments with parental and FHIT−/− HCC827 lung cancer cells in athymic nude mice (Fig. 8a).